Document:

<PAGE>   1
                                                                    EXHIBIT 10.1

                                 MEDIMMUNE, INC.

                             DISTRIBUTION AGREEMENT

         This Agreement made as of October 3, 2000 (hereinafter "EFFECTIVE
DATE") between MedImmune, Incorporated (MEDIMMUNE), Gaithersburg, Maryland,
20878, and Nova Factor, Inc. including its affiliates referred to on the
attached Exhibit A, with main offices located at 1620 Century Center Parkway
Suite 109, Memphis, TN 38134 (DISTRIBUTOR).

Pursuant to this Agreement, MEDIMMUNE appoints DISTRIBUTOR as a [***]
distributor [***] (TERRITORY) for its humanized monoclonal antibody product sold
under the trademark Synagis(R) (hereafter "PRODUCT(S)"). The parties hereto,
intending to be legally bound, hereby agree as follows:

I.       OBLIGATIONS OF MEDIMMUNE:

         A.       Shipment and Pricing to DISTRIBUTOR

                  1.       MEDIMMUNE shall sell to DISTRIBUTOR and ship the
                           PRODUCT to the above address and to addresses
                           specified in Exhibit A. MEDIMMUNE shall charge
                           DISTRIBUTOR for PRODUCTS to be sold to the [***]
                           market segment and/or through [***] (as defined in
                           Section II. F. 4) in accordance with the prices and
                           policies shown in Addendum II plus all applicable
                           Federal and State Taxes in effect on the date of each
                           shipment of the PRODUCT. Addendum II, which may be
                           modified from time to time by MEDIMMUNE, is attached
                           to this Agreement and incorporated by reference.

                  2.       [***]
                           In the event that the sale of a PRODUCT by
                           DISTRIBUTOR [***]. The [***] terms, as defined in
                           Addendum VI Paragraph two of the obligations of
                           DISTRIBUTOR attached to this Agreement and
                           incorporated by reference, for [***] shall not extend
                           to any [***].

                  3.       Discount Programs
                           In the event the goals, terms and conditions of the
                           [***]detailed in Exhibit C are met, DISTRIBUTOR shall
                           be entitled to receive [***] in Exhibit C as
                           applicable. MEDIMMUNE shall have the sole discretion
                           whether to continue the [***] or modify its terms and
                           conditions after [***].

         B.       [***] Pricing
                  For MEDIMMUNE PRODUCTS sold and shipped from DISTRIBUTOR's
                  inventory [***] and has provided [***] which requires
                  DISTRIBUTOR to accept [***], DISTRIBUTOR shall be [***].

<PAGE>   2

         C.       PRODUCT Recalls
                  MEDIMMUNE shall compensate DISTRIBUTOR for the expense
                  incurred in performing all requested recall services not due
                  to DISTRIBUTOR's negligence, willful misconduct or illegal
                  misconduct. Such compensation shall be limited to expenses
                  incurred for recall services directly related to DISTRIBUTOR'S
                  inventory in DISTRIBUTOR'S possession, unless MEDIMMUNE
                  requests additional recall services in writing from
                  DISTRIBUTOR.

         D.       [***]

         E.       Title, Insurance, and Delivery
                  Title. [***]

II.      OBLIGATIONS OF DISTRIBUTOR:

         A.       Payment for the PRODUCT
                  DISTRIBUTOR shall pay for all orders purchased by DISTRIBUTOR,
                  with payment to be rendered according to the conditions stated
                  in Addendum II. Orders shipped directly to DISTRIBUTOR's
                  customers at DISTRIBUTOR's request shall be considered as
                  those of DISTRIBUTOR and DISTRIBUTOR shall be responsible for
                  the payment of such orders. All invoices must be paid in full
                  under the terms specified in Addendum II [***]. In the event
                  DISTRIBUTOR fails to render payment for an order of the
                  PRODUCT as required, MEDIMMUNE shall have the right to
                  withhold future shipments of the PRODUCT until the outstanding
                  balance or balances have been paid.

         B.       Financial and Credit Position
                  DISTRIBUTOR shall maintain an adequate financial condition
                  satisfactory to MEDIMMUNE and substantiate such a condition
                  with audited financial statements of DISTRIBUTOR's parent
                  corporation or as otherwise reasonably requested by MEDIMMUNE.
                  [***]. If, in MEDIMMUNE's judgment, at any time before
                  shipment, the financial responsibility of the DISTRIBUTOR
                  becomes impaired or unsatisfactory to MEDIMMUNE, MEDIMMUNE
                  shall have the right to require cash payment or appropriate
                  security before shipment or shall have the right to refuse to
                  accept the order.

         C.       Payment [***]
                  DISTRIBUTOR shall reimburse MEDIMMUNE for any [***]. MEDIMMUNE
                  will issue a second invoice for the [***] for which
                  DISTRIBUTOR shall make payment within 10 (ten) days of receipt
                  of invoice.

         D.       Ordering

                                       2
<PAGE>   3

                  DISTRIBUTOR shall transmit MEDIMMUNE orders either direct via
                  EDI, fax, or phone. All orders submitted by DISTRIBUTOR shall
                  have the purchase order number clearly indicated.

         E.       Inventory

                  1.       DISTRIBUTOR [***] from MEDIMMUNE according to the
                           terms of Addendum II and the rest of this
                           Agreement. [***].

                  2.       MEDIMMUNE shall be entitled to reasonably request, at
                           any time, information regarding inventory levels of
                           PRODUCT, [***]. DISTRIBUTOR shall have the [***] this
                           information from either computer records or actual
                           physical inventory count. Upon reasonable notice,
                           MEDIMMUNE shall also have the right to inspect
                           DISTRIBUTOR's business records.

                  3.       DISTRIBUTOR shall report its [***] in accordance with
                           Addendum IV, except for sales information pertaining
                           to [***].

                  4.       DISTRIBUTOR shall maintain sufficient inventory of
                           the PRODUCT to promptly and adequately supply the
                           demand of its customers.

         F.       Services/SALES

                  1.       DISTRIBUTOR shall provide Personnel and physical
                           infrastructure for the PRODUCT as well as the
                           order-taking and delivery services necessary to meet
                           reasonable needs of customers for the PRODUCT.

                  2.       DISTRIBUTOR shall provide Marketing and Sales support
                           for the PRODUCT as required in Addendum IV, Addendum
                           V and Addendum VI attached to this Agreement and
                           incorporated by reference. All marketing, sales
                           promotion and sales efforts by. DISTRIBUTOR shall be
                           undertaken in compliance with all regulations of the
                           Food and Drug Administration and other federal and
                           state regulatory agencies.

                  3.       [***].

                  4.       "[***]" shall mean [***] by DISTRIBUTOR in response
                           to [***] of the PRODUCT in a [***] (hereinafter
                           "[***]") in exchange for [***] corresponding to the
                           [***]

                                    a.)      MEDIMMUNE and DISTRIBUTOR shall
                                             cooperate in the sharing of
                                             information regarding [***].

         G.       Pricing to Customers

                  1.       Pricing of the PRODUCT by DISTRIBUTOR shall be
                           consistent with the terms of Addendum IV or Addendum
                           VI [***].

         H.       [***]

                  1.       [***] shall [***] presented by [***] customers.

                  2.       DISTRIBUTOR shall provide MEDIMMUNE with [***] for
                           [***].

         I.       Lawful Handling

                                       3
<PAGE>   4

                  1.       With respect to the PRODUCT, DISTRIBUTOR shall take
                           such precautions as are reasonably necessary to
                           prevent its use, distribution or sale by those who
                           may not lawfully possess, use, handle, distribute or
                           sell the PRODUCT, and DISTRIBUTOR will fully comply
                           with applicable local, state, and federal laws.

                  2.       DISTRIBUTOR shall maintain all federal, state, and
                           local registrations necessary for the lawful handling
                           of the PRODUCT and immediately notify MEDIMMUNE of
                           any denial, revocation or suspension of any such
                           registration or any changes in the PRODUCT.

         J.       Proper Handling and Storage
                  DISTRIBUTOR shall handle and store the PRODUCT in a clean and
                  orderly location and in a manner which will assure that the
                  proper rotation and quality of the PRODUCT is maintained and
                  that PRODUCT is in compliance with all applicable federal,
                  state and local regulations. DISTRIBUTOR shall comply with
                  MEDIMMUNE criteria on storage and shipping the PRODUCT that
                  require special handling as provided in Addendum III attached
                  to this Agreement and incorporated by reference. DISTRIBUTOR
                  shall allow physical inspection of storage facilities at any
                  reasonable time MEDIMMUNE requests upon 10 (ten) business days
                  prior notice from MEDIMMUNE. DISTRIBUTOR shall in no way or
                  manner be permitted to repackage the PRODUCT.

         K.       Substitution
                  DISTRIBUTOR shall fill orders for the PRODUCT, only with the
                  PRODUCT. DISTRIBUTOR shall not substitute any orders for the
                  PRODUCT with products other than the PRODUCT.

         L.       Transfer of Ownership - Change in Address
                  DISTRIBUTOR shall notify MEDIMMUNE of the terms and conditions
                  of any transfer in majority ownership or control, or any
                  change in address, within a reasonable time prior to such
                  action.

         M.       Adverse Event and Product Complaint Reporting
                  DISTRIBUTOR shall forward to MedImmune, Inc. any information
                  the DISTRIBUTOR obtains from a customer regarding Adverse
                  Events (AE) or Product Complaints (PC), as defined below. The
                  CUSTOMER reporting the Adverse Event or Product Complaint
                  should be instructed to call a MedImmune, Inc. representative
                  by calling the toll free hot line, 1-877-633-4411. In
                  addition, DISTRIBUTOR shall forward patient initial, patient
                  number identification, physicians phone number, and a brief
                  description of the AE or PC via Email to
                  Drugsafety@MedImmune.com or by faxing to 240-632-4180.
                  Adverse Events (AE) definition:
                  Adverse Events (AE) means any adverse reaction associated with
                  the use of a licensed product in humans, whether or not
                  considered product related and whether or not confirmed by a
                  health professional. The term "associated with the

                                       4
<PAGE>   5

                  use of product" does not imply a causal relationship of the
                  reported event to the drug. This includes the following: An
                  adverse event occurring in the course of the use of a product
                  in professional practice; An adverse event occurring from
                  abuse of the product; An adverse event occurring from the
                  withdrawal of the product; Any significant failure of expected
                  pharmacological action; NOTE: THE TERMS "ADVERSE EVENT",
                  "ADVERSE BIOLOGIC REACTION", "ADVERSE DRUG REACTION" OR
                  "ADVERSE REACTION" ARE USED SYNONYMOUSLY.

                  Product complaint definition:
                  Complai is a claim or expression of displeasure,
                  dissatisfaction or annoyance with a licensed product, licensed
                  product related materials or licensed product-related
                  information. It may or may not involve a formal charge or
                  accusation. It may be related to identity, purity, potency,
                  safety or quality of the product. If the complaint involves a
                  medical event in a patient, it must be considered an adverse
                  event.

III.     RETURNS

         A.       [***] that are a result of returns are the responsibility of
                  [***]. Furthermore, MEDIMMUNE will not accept merchandise that
                  has been [***]. All returns require prior approval by
                  MEDIMMUNE. No other returns will be accepted.

         B.       [***]. Proper documentation, including certification that
                  [***], must accompany every return or claim. [***] for [***]
                  will only be issued after MEDIMMUNE has received the [***]
                  from DISTRIBUTOR. DISTRIBUTOR shall report all claims for
                  returns of PRODUCT shipped by MEDIMMUNE [***] receiving date.
                  [***].

         C.       The provisions of this section of further subject to those of
                  [***].

IV.      GENERAL PROVISIONS

         A.       All orders are subject to acceptance and approval by
                  MEDIMMUNE.

         B.       Neither MEDIMMUNE nor DISTRIBUTOR shall be liable to the other
                  for failing to do as agreed where such failure is the result
                  of a strike or other labor disturbance, fire, flood,
                  earthquake, storm, governmental action, or other reason beyond
                  its control.

         C.       [***]

         D.       [***]

                                       5
<PAGE>   6

         E.       No business unit, subsidiary, affiliate, division or operation
                  conducted by DISTRIBUTOR other than those listed on Exhibit A
                  shall be bound by the terms and conditions, or entitled to the
                  rights, of this Agreement. Nova Factor, Inc. shall be liable
                  for any and all breaches or failures, including the failure to
                  render payment for the PRODUCT, committed by the entities
                  listed on Exhibit A.

         F.       This Agreement may be changed or amended only in writing
                  signed by duly authorized representatives of MEDIMMUNE and
                  DISTRIBUTOR, and in the case of MEDIMMUNE, only by an
                  authorized representative from its office in Gaithersburg. All
                  attachments and addenda to this Agreement are hereby
                  incorporated by reference.

         G.       This Agreement, and any rights or obligations hereunder, shall
                  not be assigned by either party without the written consent of
                  the other party, except that either party may otherwise assign
                  its respective rights and transfer its respective duties to
                  any assignee of all or substantially all of its business (or
                  that portion thereof to which this Agreement relates) that is
                  not a subsidiary or division of its parent corporation or in
                  the event of its merger or consolidation or similar
                  transaction with a business entity other than a subsidiary or
                  division of its parent corporation. Either party may assign
                  its respective rights and/or transfer its respective duties to
                  a subsidiary or division of its parent corporation only upon
                  the written permission of the other party which shall not be
                  unreasonably withheld.

         H.       This Agreement shall renew automatically on the one year
                  anniversary of the EFFECTIVE DATE and every year thereafter
                  unless either terminates this Agreement with a 30 (thirty) day
                  notice prior to the anniversary date. During its term, the
                  Agreement may be terminated by either party upon thirty (30)
                  days written notice mailed to the other at the address set
                  forth above or terminated immediately for any breach of the
                  terms and conditions of this agreement.

         I.       During the term of the Agreement, each party may find it
                  necessary to disclose confidential and proprietary information
                  to the other (hereinafter "INFORMATION"). The INFORMATION may
                  include but not be limited to pricing generally [***], price
                  quotations for the PRODUCT by DISTRIBUTOR or MEDIMMUNE,
                  delivery schedules, manufacturing schedules, sales amounts and
                  sales figures. During the term of this Agreement and for 5
                  (five) years thereafter, irrespective of any termination
                  earlier than the expiration of the term of this Agreement,
                  each party shall maintain the INFORMATION in confidence and
                  shall not reveal the INFORMATION to third parties without the
                  written consent of the disclosing party, except as required by
                  law, regulation, or legal process. These restrictions shall
                  not apply to INFORMATION that:

                  a)       becomes public knowledge without the fault of the
                           receiving party;

                  b)       is already in the possession of the receiving party
                           as shown by competent evidence;

                                       6
<PAGE>   7

                  c)       is disclosed to the receiving party by a third party
                           with no obligation to the disclosing party to
                           maintain its confidentiality;

                  d)       is independently developed by the receiving party
                           without reference to the INFORMATION of the other
                           party.

         J.       Except for any announcement intended solely for internal
                  distribution by other party or any disclosure required by
                  legal, accounting, or regulatory requirements beyond the
                  reasonable control of the other party, all media releases,
                  public announcements, or public disclosures (including, but
                  not limited to, promotional or marketing material) by the
                  other party its employees or agents relating to this Agreement
                  or its subject matter, or including the name of MEDIMMUNE or
                  any affiliate, shall be coordinated with and approved in
                  writing by MEDIMMUNE prior to the release thereof.

         K.       This Agreement supersedes all prior contracts, agreements, and
                  understandings between MEDIMMUNE and DISTRIBUTOR with regard
                  to its subject matter.

         L.       This Agreement shall be construed in accordance with, and
                  governed by, the laws of the State of [***].

         M.       Unauthorized deductions are in violation of this Agreement and
                  will result in delayed shipments or canceled orders.

IN WITNESS WHEREOF, the parties hereto have executed this DISTRIBUTOR AGREEMENT
as of the date set forth above.

         MEDIMMUNE                                       DISTRIBUTOR

By:      /s/ Armando Anido                      By:      /s/ Randy Grow
   ---------------------------------               -----------------------------
         Armando Anido
Title:   Senior Vice President,
         Sales and Marketing
Date:             10/3/00                       Date:        9/29/00
     -------------------------------                 ---------------------------

                                       7
<PAGE>   8

                                    EXHIBIT A

<TABLE>
<S>                                           <C>
Nova Factor, Inc.                             AHI Pharmacies, Inc.
1620 Century Center Pkwy Suite 109            40880B County Center Drive Suite M
Memphis, Tennessee 38134                      Temecula, CA 92691
Tel: 877-482-5927                             Key Contact: Patricia Morrison, R.Ph.
Fax: 877-369-3447                             Tel: 909-694-4226
Key Contact: Bob Cates, Pharm.D.              Fax: 800-233-3784
[***]                                         [***]

Texas Health Pharmaceutical Resources         AHI Pharmacies, Inc.
2100 Highway 360, Suite 604                   9741-A Southern Pines Blvd.
Grand Prairie, Texas 75050                    Charlotte, NC 28273
Key Contact: Michael Rizk, Pharm.D.           Key Contact: Joe Cooke, R.Ph.
Tel: 972-602-3471                             Tel: 704-522-6345
Fax: 972-602-8312                             Fax: 704-527-5490
[***]                                         [***]

Cook Children's Home Health                   AHI Pharmacies, Inc.
2100 Highway 360, Suite 605A                  5393 Roosevelt Blvd. Suite 21
Grand Prairie, Texas 75050                    Jacksonville, FL 32210
Key Contact: Michael Rizk, Pharm.D.           Key Contact: Gary Roberts, Pharm.D.
Tel: 972-602-3471                             Tel: 904-388-2688
Fax: 972-602-1521                             Fax: 904-388-9779
[***]                                         [***]
</TABLE>

                                       8
<PAGE>   9

<TABLE>
<S>                                           <C>
Nova Factor, Inc.                             CM FactorCare
3576 Loma Ridge Drive                         1000 Sunset Ridge Road Suite 200
Hoover, Alabama 35216                         Northbrook, IL 60062-4010
Key Contact: Nancy Bishop, R.Ph.              Key Contact: Bob Cates, D.Ph.
Tel.: 205-823-1172                            Tel: 847-562-9966
Fax: 205-823-1265                             Fax: 847-562-9988
[***]                                         [***]

Childrens Home Services                       Children's Biotech Pharmacy Services
dba Childrens Home Care                       111 Michigan Avenue # W4-600
4650 Sunset Blvd. Mail Stop 16                Washington, DC 20010-2970
Los Angeles, CA 90027                         Tel: 202-884-3716
Key Contact: Bob Cates, D. Ph.                Key Contact: Doug Scheckelhoff
Tel: 213-669-2401
Fax: 213-668-7676
[***]

Le Bonheur Children's Medical Center
50 North Dunlap
Memphis, TN 38103
901-572-3000
Key Contact: Bert Price
</TABLE>

                                       9
<PAGE>   10

ATTACHMENTS:

ADDENDUM I:   RETURNS POLICY
ADDENDUM II:  DISTRIBUTOR PRICE LIST AND TERMS
ADDENDUM III: STORAGE AND SHIPPING GUIDELINES
ADDENDUM IV:  [***]
ADDENDUM V:   DISTRIBUTOR [***] REQUIREMENTS
ADDENDUM VI:  [***]

                                       10
<PAGE>   11

                                   ADDENDUM I

                                 RETURNS POLICY

                MedImmune, Inc. Return Policy and Instructions:

Returnable PRODUCT:

-        [***] that are [***] and have [***]. ([***] must be documented.)

-        [***] from MEDIMMUNE and [***] is reported [***] of receipt.

                          No other returns are accepted.

          These procedures must be followed when returning Synagis(R):

         -        Contact MEDIMMUNE Customer Service at 1(877) 633-4411 to
                  obtain a Return Authorization Form.

         -        COMPLETELY fill out the Return Authorization form, including
                  [***], courier, pick-up date and signature.

         -        INCLUDE THE RETURN AUTHORIZATION FORM AND A [***] WITH EACH
                  RETURN. NO returns will be accepted without the form. Please
                  reference the Return Authorization document number on your
                  [***].

         -        FOLLOW THE ATTACHED PACKAGING INSTRUCTIONS FOR EACH TYPE OF
                  RETURN.

         -        The Wholesaler has agreed to maintain [***] necessary for the
                  [***] of this product. Therefore, [***], will not be honored.

                  If any of the above procedures have not been followed,
                  MedImmune will not be held responsible for [***] of
                  merchandise. Credits will be issued to DISTRIBUTOR at the net
                  purchase price for products returned correctly within (30)
                  days from the day that DISTRIBUTOR notifies MEDIMMUNE the
                  tracking number and any pertinent information via fax that a
                  return shipment has taken place.

         -        RETURN SHIPMENTS WILL ONLY BE RECEIVED BY MEDIMMUNE DURING THE
                  HOURS OF 9:00 A.M. TO 5:00 P.M. MONDAY THROUGH FRIDAY, EXCEPT
                  ON HOLIDAYS. DO NOT SHIP RETURNS ON FRIDAYS!

Please contact MedImmune Customer Service at 1(877) 633-4411, if you have any
questions. Thank you.

                      MedImmune Fax number: (301) 527-4210

                                      [***]

                                       11
<PAGE>   12

                                  ADDENDUM II:

               DISTRIBUTOR PRICING (CURRENT AS OF AUGUST 1, 2000)

<TABLE>
<CAPTION>
                                                                         [***]
                                                                         -----
<S>                                                                      <C>
SYNAGIS(R)(NDC 60574-4111-1), (palivizumab); 100mg single dose vial      $[***]
SYNAGIS(R)(NDC 60574-4112-1), (palivizumab);  50mg single dose vial      $[***]

[***]

         TERMS    [***]

         [***]
</TABLE>

                                       12
<PAGE>   13

                                  ADDENDUM III

                       STORAGE AND SHIPMENT OF SYNAGIS(R)

-        [***]

                                       13
<PAGE>   14

                                   ADDENDUM IV

                      DISTRIBUTOR PERFORMANCE REQUIREMENTS

-        DISTRIBUTOR will submit [***] to MEDIMMUNE [***]. Data must be
         submitted [***] according to the format [***].

-        DISTRIBUTOR will [***].

-        DISTRIBUTOR markup for both wholesaler sales and sales from other than
         the [***] program to its customers/[***].

-        DISTRIBUTOR will provide MEDIMMUNE with [***] for purposes of market
         research and mailings only. Information will be agreed upon by both
         parties and will remain confidential. However, DISTRIBUTOR shall not be
         required to provide [***] pertaining [***] for which DISTRIBUTOR has a
         contractual obligation not to disclose to third parties.

-        DISTRIBUTOR will [***] DISTRIBUTOR [***], notifying DISTRIBUTOR [***].

-        DISTRIBUTOR will provide support, where appropriate, to MEDIMMUNE
         [***].

-        DISTRIBUTOR will use telemarketing staff, internal and external sales
         staff, direct marketing and other promotional or advertising materials
         that have been preapproved by MEDIMMUNE in order to promote PRODUCTS.

-        If any account of the DISTRIBUTOR becomes a credit risk DISTRIBUTOR
         shall give MEDIMMUNE [***] to the termination of the subject account
         and such notification shall be delivered via e-mail to the following
         address: Data@MedImmune.com.

                                       14
<PAGE>   15

                                   ADDENDUM V

                         DISTRIBUTOR [***] REQUIREMENTS

-        DISTRIBUTOR [***] TO [***] WITH RESPECT TO [***].

-        DISTRIBUTOR WILL ATTEMPT TO [***], AND TO [***] PRODUCT TO [***]
         THEREUNDER.

-        IN THE EVENT DISTRIBUTOR IS UNABLE TO [***], DISTRIBUTOR WILL SEND
         [***] TO ANY [***].

                                       15

<PAGE>   16

                                EXCELSPREADSHEET
                                    EXHIBIT B

<TABLE>
<S>      <C>     <C>     <C>     <C>      <C>     <C>    <C>     <C>     <C>    <C>    <C>
--------------------------------------------------------------------------------------------------
[***]    [***]   [***]   [***]   [***]    [***]   [***]  [***]   [***]   [***]  [***]  [***]
--------------------------------------------------------------------------------------------------
[***]    [***]   [***]   [***]   [***]                   [***]                  [***]  [***]
--------------------------------------------------------------------------------------------------
[***]    [***]   [***]   [***]   [***]                   [***]                  [***]  [***]
--------------------------------------------------------------------------------------------------
[***]    [***]   [***]   [***]   [***]                   [***]                  [***]  [***]
--------------------------------------------------------------------------------------------------
[***]    [***]   [***]   [***]   [***]                   [***]                  [***]  [***]
--------------------------------------------------------------------------------------------------
</TABLE>

[***]

                                       16
<PAGE>   17

ADDENDUM VI

[***]

                                       17
<PAGE>   18

                                    EXHIBIT C

[***]

                                       18
<PAGE>   19

                                                                     EXHIBIT C-1

                            SYNAGIS(R) [***] PROGRAM

-        [***]

                                       19
<PAGE>   20

                                                                     EXHIBIT C-2

                      CRITERIA FOR BEING A MEDIMMUNE [***]

-        [***]

                                       20
<PAGE>   21

                                                                     EXHIBIT C-3

                    REQUIREMENTS FOR BEING A MEDIMMUNE [***]

-        [***]

                                       21
<PAGE>   22

                                                                     EXHIBIT C-4

                                     [***]
                                     [***]

                                       22
<PAGE>   23

                                                                     EXHIBIT C-5

                             SYNAGIS(R) OUTCOME DATA
                      REQUIRED DATA FROM [***] DISTRIBUTORS

Nova Factor, Inc. will put forth its best efforts to obtain the following
information.

Due to patient confidentiality, we do not wish to receive individual patient
information. However, the following aggregated data, updated on a monthly basis
from 07/01/00 through 06/30/01, and a final aggregated data by 07/31/01 is
required:

1)       # of patients [***]

2)       Number of patients [***].

3)       Location of first injection [***].

4)       Mean [***] at first injection (with ranges).

5)       Mean [***] (with ranges).

6)       Breakdown [***] as follows: [***]

7)       Breakdown [***] as follows: [***].

8)       Mean [***] (with ranges).

9)       [***]

10)      Breakdown by [***] as follows [***].

11)      # With [***].

12)      # With [***] broken down as [***].

13)      # With [***], specify e.g., [***].

14)      [***]  mix broken down as follows: [***].

15)      Number of [***], broken down by insurance type.

                                       23
<PAGE>   24

                                                                    EXHIBIT C-6A

                       SUPPLY SERVICE REPORTS REQUIRED BY
                                      [***]

Distributor Report Template

The goal of this template is to bring consistency to the way MEDIMMUNE receives
data regarding distribution of Synagis(R). This will enable us to better support
distributor efforts ensure that patients have access to the product.

Description of fields

Although many of the fields are self explanatory, those that have special needs
associated with them are explained below:

1.       [***] - a consistent spelling of the [***] should be established for
         data entry. A good example is [***] is abbreviated as [***] and
         unabbreviated in the report, payer identification becomes difficult.
         Similarly a protocol for [***] should be established as well. [***].

2.       [***] - Specific [***] if known, otherwise the abbreviations [***]
         should be entered.

3.       [***] % - the percentage of [***] that is associated with [***] for
         Synagis(R).

4.       Status - This is to identify the broad category a patient referral
         falls into. The preferred terms are: [***].

5.       Explanation -further explanation of [***]. Provides categories for
         [***]. Examples: Out of Network, [***].

6.       Action/Comments - Free text that describes action was taken, examples -
         referred to XXX [***], referred [***], referred to [***]

-        Further explanation of [***] decisions, examples -[***].

-        Number of [***] for a patient who was [***] or has [***].

                                       24
<PAGE>   25

                                  EXHIBIT C-6B

<TABLE>
  <S>        <C>      <C>     <C>  <C>    <C>          <C>       <C>         <C>        <C>         <C>      <C>           <C>
  ---------- -------- ------- ---- ------ ------------ --------- ----------- ---------- ----------- -------- ------------- ---------
    [***]     [***]    [**]         [*]      [***]                 [***]       [***]        [**]     [***]      [***]          [***]
  ---------- -------- ------- ---- ------ ------------ --------- ----------- ---------- ----------- -------- ------------- ---------
                                             [***]                                                   [***]      [***]          [***]
  ---------- -------- ------- ---- ------ ------------ --------- ----------- ---------- ----------- -------- ------------- ---------
                                                                                                     [***]
  ---------- -------- ------- ---- ------ ------------ --------- ----------- ---------- ----------- -------- ------------- ---------
                                                                                                     [***]
  ---------- -------- ------- ---- ------ ------------ --------- ----------- ---------- ----------- -------- ------------- ---------
                                                                                                     [***]
  ---------- -------- ------- ---- ------ ------------ --------- ----------- ---------- ----------- -------- -------------
</TABLE>

                                       25<PAGE>   1
                                                                    EXHIBIT 10.2

                      NON-QUALIFIED STOCK OPTION AGREEMENT
                                    under the
                          ACCREDO HEALTH, INCORPORATED
                          1999 LONG-TERM INCENTIVE PLAN

              Optionee:              Patrick J. Welsh
                       -----------------------------------------------------

              Number Shares Subject to Option:    10,000
                                              ------------------------------

              Exercise Price per Share:          $41.625
                                       -------------------------------------

              Date of Grant:                     November 1, 2000
                            ------------------------------------------------

         1.       Grant of Option. Accredo Health, Incorporated (the "Company")
hereby grants to the Optionee named above (the "Optionee"), under the Accredo
Health, Incorporated 1999 Long-Term Incentive Plan (the "Plan"), a Non-Qualified
Stock Option to purchase, on the terms and conditions set forth in this
agreement (this "Option Agreement"), the number of shares indicated above of the
Company's $0.01 par value common stock (the "Stock"), at the exercise price per
share set forth above (the "Option"). Capitalized terms used herein and not
otherwise defined shall have the meanings assigned such terms in the Plan.

         2.       Vesting of Option. The Option shall be 100% vested upon the
date of grant.

         3.       Period of Option and Limitations on Right to Exercise. The
Option will, to the extent not previously exercised, lapse under the earliest of
the following circumstances; provided, however, that the Committee may, prior to
the lapse of the Option under the circumstances described in paragraph below,
provide in writing that the Option will extend until a later date:

         (a)      The Option shall lapse as of 5:00 p.m., Eastern Time, on the
tenth anniversary of the date of grant (the "Expiration Date").

         (b)      The Option shall lapse three months after the Optionee's
termination of service as a director for any reason.

         If the Optionee or his beneficiary exercises an Option after
termination of service as a director, the Option may be exercised only with
respect to the shares that were otherwise vested on the Optionee's termination
of service (including vesting by acceleration in accordance with Article 13 of
the Plan).

<PAGE>   2

         4.       Exercise of Option. The Option shall be exercised by written
notice directed to the Secretary of the Company at the principal executive
offices of the Company, in substantially the form attached hereto as Exhibit A,
or such other form as the Committee may approve. Unless the exercise is a
broker-assisted "cashless exercise" as described below, such written notice
shall be accompanied by full payment in cash, shares of Stock previously
acquired by the Optionee, or any combination thereof, for the number of shares
specified in such written notice; provided, however, that if shares of Stock are
used to pay the exercise price, such shares must have been held by the Optionee
for at least six months. The Fair Market Value of the surrendered Stock as of
the last trading day immediately prior to the exercise date shall be used in
valuing Stock used in payment of the exercise price. To the extent permitted
under Regulation T of the Federal Reserve Board, and subject to applicable
securities laws, the Option may be exercised through a broker in a so-called
"cashless exercise" whereby the broker sells the Option shares and delivers cash
sales proceeds to the Company in payment of the exercise price. In such case,
the date of exercise shall be deemed to be the date on which notice of exercise
is received by the Company and the exercise price shall be delivered to the
Company on the settlement date.

         Subject to the terms of this Option Agreement, the Option may be
exercised at any time and without regard to any other option held by the
Optionee to purchase stock of the Company. Upon the Optionee's death, the Option
may be exercised by the Optionee's beneficiary.

         5.       Beneficiary Designation. The Optionee, by written notice to
the Committee, may designate one or more persons (and from time to time change
such designation) including the Optionee's legal representative, who, by reason
of the Optionee's death, shall acquire the right to exercise all or a portion of
the Option. If no beneficiary has been designated or survives the Optionee, the
Option may be exercised by the personal representative of the Optionee's estate.
If the person with exercise rights desires to exercise any portion of the
Option, such person must do so in accordance with the terms and conditions of
this Agreement and the Plan.

         6.       Withholding. The Company has the authority and the right to
deduct or withhold, or require the Optionee to remit to the Company, an amount
sufficient to satisfy federal, state, and local taxes (including the Optionee's
FICA obligation) required by law to be withheld with respect to any taxable
event arising as a result of the exercise of the Option. Such withholding
requirement may be satisfied, in whole or in part, at the election of the
Company, by withholding from the Option shares of Stock having a Fair Market
Value on the date of withholding equal to the minimum amount (and not any
greater amount) required to be withheld for tax purposes, all in accordance with
such procedures as the Committee establishes.

         7.       Limitation of Rights. The Option does not confer to the
Optionee or the Optionee's personal representative any rights of a shareholder
of the Company unless and until shares of Stock are in fact issued to such
person in connection with the exercise of

                                      -2-
<PAGE>   3

the Option. Nothing in this Option Agreement shall confer upon the Optionee any
right to continue as a director of the Company or any Parent or Subsidiary.

         8.       Stock Reserve. The Company shall at all times during the term
of this Option Agreement reserve and keep available such number of shares of
Stock as will be sufficient to satisfy the requirements of this Option
Agreement.

         9.       Restrictions on Transfer and Pledge. The Option may not be
pledged, encumbered, or hypothecated to or in favor of any party other than the
Company or a Parent or Subsidiary, or be subject to any lien, obligation, or
liability of the Optionee to any other party other than the Company or a Parent
or Subsidiary. The Option is not assignable or transferable by the Optionee
other than by will or the laws of descent and distribution or pursuant to a
domestic relations order that would satisfy Section 414(p)(1)(A) of the Code;
provided, however, that the Committee may (but need not) permit other transfers
where the Committee concludes that such transferability (i) does not result in
accelerated taxation and (ii) is otherwise appropriate and desirable, taking
into account any factors deemed relevant, including without limitation, state or
federal tax or securities laws applicable to transferable options. The Option
may be exercised during the lifetime of the Optionee only by the Optionee or any
permitted transferee.

         10.      Restrictions on Issuance of Shares. If at any time the Board
shall determine in its discretion, that listing, registration or qualification
of the shares of Stock covered by the Option upon any securities exchange or
under any state or federal law, or the consent or approval of any governmental
regulatory body, is necessary or desirable as a condition to the exercise of the
Option, the Option may not be exercised in whole or in part unless and until
such listing, registration, qualification, consent or approval shall have been
effected or obtained free of any conditions not acceptable to the Board.

         11.      Plan Controls. The terms contained in the Plan are
incorporated into and made a part of this Option Agreement and this Option
Agreement shall be governed by and construed in accordance with the Plan. In the
event of any actual or alleged conflict between the provisions of the Plan and
the provisions of this Option Agreement, the provisions of the Plan shall be
controlling and determinative.

         12.      Successors. This Option Agreement shall be binding upon any
successor of the Company, in accordance with the terms of this Option Agreement
and the Plan.

         13.      Severability. If any one or more of the provisions contained
in this Option Agreement are invalid, illegal or unenforceable, the other
provisions of this Option Agreement will be construed and enforced as if the
invalid, illegal or unenforceable provision had never been included.

                                      -3-
<PAGE>   4

         14.      Notice. Notices and communications under this Option Agreement
must be in writing and either personally delivered or sent by registered or
certified United States mail, return receipt requested, postage prepaid. Notices
to the Company must be addressed to:

                  Accredo Health, Incorporated
                  1640 Century Center Parkway
                  Suite 101
                  Memphis, Tennessee  38134
                  Attn:  Secretary

or any other address designated by the Company in a written notice to the
Optionee. Notices to the Optionee will be directed to the address of the
Optionee then currently on file with the Company, or at any other address given
by the Optionee in a written notice to the Company.

         15.      Binding Effect. The grant of the Options referenced herein is
subject to Optionee being bound by all of the terms set out in this Agreement.
The acceptance of the Options and the exercise of any right hereunder, including
but not being limited to the giving of written notice to exercise any Option,
shall constitute conclusive evidence of acceptance by the Optionee of all of the
terms and conditions set out herein, and Optionee by such actions shall be bound
by, and shall be deemed to have agreed to these terms and conditions, the same
as if Optionee had affixed his or her signature to this Incentive Stock Option
Agreement.

         IN WITNESS WHEREOF, Accredo Health, Incorporated, acting by and through
its duly authorized officers, has caused this Option Agreement to be executed,
all as of the day and year first above written.

                                        ACCREDO HEALTH, INCORPORATED

                                        By: /s/  Thomas W. Bell, Jr.
                                           ---------------------------------

                                        Name:  Thomas W. Bell, Jr.
                                        Title: Sr. Vice President and
                                               General Counsel

                                      -4-
<PAGE>   5

                                    EXHIBIT A

                    NOTICE OF EXERCISE OF OPTION TO PURCHASE
                                 COMMON STOCK OF
                          ACCREDO HEALTH, INCORPORATED

Name
     ------------------------------------

Address:
         --------------------------------

         --------------------------------
Date
     ------------------------------------

Accredo Health, Incorporated
1640 Century Center Parkway
Suite 101
Memphis, Tennessee 38134
Attn: Secretary

Re:      Exercise of Non-Qualified Stock Option

         I elect to purchase ______________ shares of Common Stock of Accredo
Health, Incorporated (the "Company") pursuant to the Accredo Health,
Incorporated Non-Qualified Stock Option Agreement dated ______________ and the
Accredo Health, Incorporated 1999 Long-Term Incentive Plan. The purchase will
take place on the Exercise Date, which will be (i) as soon as practicable
following the date this notice and all other necessary forms and payments are
received by the Company, unless I specify a later date (not to exceed 30 days
following the date of this notice), or (ii) in the case of a Broker-assisted
cashless exercise (as indicated below), the date of this notice.

         On or before the Exercise Date (or, in the case of a Broker-assisted
cashless exercise, on the settlement date following the Exercise Date), I will
pay the full exercise price in the form specified below (check one):

[ ]      Cash Only: by delivering a check to the Company for $___________.

[ ]      Cash and Shares: by delivering a check to the Company for $_________
         for the part of the exercise price. I will pay the balance of the
         exercise price by delivering to the Company a stock certificate with my
         endorsement for shares of Company Stock that I have owned for at least
         six months. If the number of shares of Company Stock represented by
         such stock certificate exceeds the number needed to pay the exercise
         price, the Company will issue me a new stock certificate for the
         excess.

[ ]      Shares Only: by delivering to the Company a stock certificate with my
         endorsement for shares of Company Stock that I have owned for at least
         six

<PAGE>   6

         months. If the number of shares of Company Stock represented by such
         stock certificate exceeds the number needed to pay the exercise price,
         the Company will issue me a new stock certificate for the excess.

[ ]      Cash From Broker: by delivering the purchase price from
         _______________________, a broker, dealer or other "creditor" as
         defined by Regulation T issued by the Board of Governors of the Federal
         Reserve System (the "Broker"). I authorize the Company to issue a stock
         certificate in the number of shares indicated above in the name of the
         Broker in accordance with instructions received by the Company from the
         Broker and to deliver such stock certificate directly to the Broker (or
         to any other party specified in the instructions from the Broker) upon
         receiving the exercise price from the Broker.

         On or before the Exercise Date, I will pay satisfy any applicable tax
withholding obligations in the form specified below (check one):

[ ]      Cash Only: by delivering a check to the Company for the full tax
         withholding amount.

[ ]      Cash and Shares: by delivering a check to the Company for $_________
         for part of the tax withholding amount. I will pay the balance of the
         tax withholding amount by delivering to the Company a stock certificate
         with my endorsement for shares of Company Stock that I have owned for
         at least six months. If the number of shares of Company Stock
         represented by such stock certificate exceeds the number needed to pay
         the tax withholding amount, the Company will issue me a new stock
         certificate for the excess.

[ ]      Shares Only: by delivering to the Company a stock certificate with my
         endorsement for shares of Company Stock that I have owned for at least
         six months. If the number of shares of Company Stock represented by
         such stock certificate exceeds the number needed to pay the tax
         withholding amount, the Company will issue me a new stock certificate
         for the excess.

[ ]      Withholding of Shares to Cover Minimum Obligation: by having the
         Company withhold shares of Stock from the Option having a Fair Market
         Value on the date of withholding equal to the minimum amount (and not
         any greater amount) required to be withheld for tax purposes. Only
         whole shares may be withheld.

                                      -2-
<PAGE>   7

         Please deliver the stock certificate to me (unless I have chosen to pay
the purchase price through a Broker).

                                            Very truly yours,

                                            ------------------------------------

AGREED TO AND ACCEPTED:

ACCREDO HEALTH, INCORPORATED

By:
    -----------------------------------

Title:
       --------------------------------

Number of Option Shares
Exercised:
           ----------------------------

Number of Option Shares
Remaining:
           ----------------------------

Date:
      ---------------------------------

                                      -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]